• Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Repligen Corp

+ Add to Watchlist

RGEN:US

20.2400 USD 0.4000 2.02%

As of 20:10:00 ET on 12/26/2014.

Snapshot for Repligen Corp (RGEN)

Open: 20.0000 Day's Range: 19.7951 - 20.5100 Volume: 166,388
Previous Close: 19.8400 52wk Range: 11.7000 - 26.7500 1-Yr Rtn: +59.87%

Stock Chart for RGEN

No chart data available.
  • RGEN:US 20.2400
  • 1D
  • 1M
  • 1Y
19.8400
Interactive RGEN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for RGEN

Current P/E Ratio (ttm) 56.0592
Estimated P/E(12/2014) 76.9582
Relative P/E vs. SPX 3.0306
Earnings Per Share (USD) (ttm) 0.3610
Est. EPS (USD) (12/2014) 0.2630
Est. PEG Ratio -
Market Cap (M USD) 662.29
Shares Outstanding (M) 32.72
30 Day Average Volume 300,943
Price/Book (mrq) 5.7766
Price/Sale (ttm) 10.4182
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/06/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for RGEN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for RGEN

Repligen Corporation is a biotechnology company. The Company develops therapeutics for the treatment of diseases of the central nervous system. Repligen owns owns intellectual property on monoclonal antibody and antibody fusion products.

Walter C HerlihyPresident/CEO/TreasurerJon K SnodgresChief Financial Officer
Tony J HuntChief Operating OfficerJames R RuscheSenior VP:Research & Dev
More Company Profile & Key Executives for RGEN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil